CN117320736A - 包含柠檬明串珠菌菌株作为有效成分的用于预防或治疗胆汁淤积性肝病的药物组合物 - Google Patents
包含柠檬明串珠菌菌株作为有效成分的用于预防或治疗胆汁淤积性肝病的药物组合物 Download PDFInfo
- Publication number
- CN117320736A CN117320736A CN202280014031.5A CN202280014031A CN117320736A CN 117320736 A CN117320736 A CN 117320736A CN 202280014031 A CN202280014031 A CN 202280014031A CN 117320736 A CN117320736 A CN 117320736A
- Authority
- CN
- China
- Prior art keywords
- preventing
- cholestatic liver
- liver disease
- composition
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010008635 Cholestasis Diseases 0.000 title claims abstract description 46
- 241001468192 Leuconostoc citreum Species 0.000 title claims abstract description 32
- 239000004480 active ingredient Substances 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims abstract description 13
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims abstract description 13
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims abstract description 13
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims abstract description 9
- 208000010157 sclerosing cholangitis Diseases 0.000 claims abstract description 9
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims abstract description 8
- 241000192132 Leuconostoc Species 0.000 claims description 21
- 241000699670 Mus sp. Species 0.000 claims description 17
- 239000003674 animal food additive Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 9
- 235000013373 food additive Nutrition 0.000 claims description 8
- 239000002778 food additive Substances 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 244000144972 livestock Species 0.000 claims description 7
- 235000015067 sauces Nutrition 0.000 claims description 7
- 241000286209 Phasianidae Species 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- 241000272517 Anseriformes Species 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 4
- 235000015243 ice cream Nutrition 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims description 2
- 241000700198 Cavia Species 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 241000283086 Equidae Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000277331 Salmonidae Species 0.000 claims description 2
- 241000282887 Suidae Species 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 235000012970 cakes Nutrition 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000013330 chicken meat Nutrition 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000021438 curry Nutrition 0.000 claims description 2
- 235000013332 fish product Nutrition 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 235000013555 soy sauce Nutrition 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 239000000052 vinegar Substances 0.000 claims description 2
- 235000021419 vinegar Nutrition 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims 1
- 240000004160 Capsicum annuum Species 0.000 claims 1
- 241000252210 Cyprinidae Species 0.000 claims 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims 1
- 240000003768 Solanum lycopersicum Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 235000021109 kimchi Nutrition 0.000 claims 1
- 235000020991 processed meat Nutrition 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 13
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 210000000013 bile duct Anatomy 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 210000005228 liver tissue Anatomy 0.000 description 12
- 238000010171 animal model Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000003445 biliary tract Anatomy 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 10
- 235000005979 Citrus limon Nutrition 0.000 description 9
- 244000131522 Citrus pyriformis Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 235000012149 noodles Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 231100000359 cholestasis Toxicity 0.000 description 4
- 230000007870 cholestasis Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 101150008656 COL1A1 gene Proteins 0.000 description 3
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001587 cholestatic effect Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- -1 etc. Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010067969 Cholestatic liver injury Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002529 anti-mitochondrial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000010610 frozen noodles Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000014059 processed cheese Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 201000010304 suppurative cholangitis Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种用于预防、改善或治疗胆汁淤积性肝病,具体地,原发性胆汁性肝硬化、原发性硬化性胆管炎的组合物,所述组合物包含柠檬明串珠菌菌株或其的培养物作为有效成分。根据本发明的组合物,对各种胆汁淤积性肝病表现出优异的预防和治疗效果,因此,可以有效地用作用于治疗、预防或改善人或动物的胆汁淤积性肝病的组合物。
Description
技术领域
本发明涉及一种用于预防、改善或治疗胆汁淤积性肝病,具体地,原发性胆汁性肝硬化(Primary biliary cirrhosis;PBC)、原发性硬化性胆管炎(Primary sclerosingcholangitis;PSC)的组合物,所述组合物包含柠檬明串珠菌(Leuconostoc citreum)菌株或其的培养物作为有效成分。
背景技术
胆汁淤积性肝病(cholestatic liver injury)是由胆汁酸和脂质的蓄积而引起的疾病。肝脏调节中枢脂质代谢过程,包括脂肪酸合成、线粒体β-氧化及磷脂运输。胆道梗阻(biliary obstruction)或肝损伤引起的胆汁分泌受损会扰乱胆固醇和磷脂代谢。在胆道结扎(bileduct ligation,BDL)大鼠模型中,肝脏脂质浓度没有改变,而极低密度脂蛋白(very low-density lipoprotein,VLDL)胆固醇和低密度脂蛋白(low-densitylipoprotein,LDL)胆固醇的血清水平显著升高(T.Kamisako等人,Hepatology Research,第25卷,第2期,第99页至第104页,2003年)。
PBC是胆汁淤积性肝病之一,尽管其为一种相对罕见的表现出慢性胆汁淤积性疾病特征,但由于其独特的临床表现和病理生理学引起了诸多消化科医生的关注。PBC出现在所有种族中,患病率为每100万人口中有100至200人左右,发病年龄通常为30至70岁,在中年女性中尤为多见,据了解,如果家庭中有患者,则女性家庭成员中出现PBC患者的可能性比对照组高约1000倍。可伴有多种自身免疫性疾病,大多数患者体内可发现抗线粒体抗体,这是一特征。组织学上,其特征为进行性非化脓性胆管炎(nonsuppurative cholangitis)。
PSC与PBC一样,是一种病因不明的慢性胆汁淤积性疾病,其特征为显示肝内和肝外胆道的炎症性纤维化和破坏,并且经常伴有炎症性肠病。如PBC进展导致肝硬化和并发症,但没有有效的治疗方法。
PSC的确切原因尚不清楚,但认为与自身免疫反应、肝门静脉菌血症、遗传易感性有关。患者体内出现多种自身抗体(ANA、SMA、ANCA),血液中的补体和免疫复合物增加,并伴随炎症性肠病等,这一事实表明自身免疫机制可能是原因。PSC在患者家庭成员中的患病率较高,认为HLA关联性参与某些已知遗传易感性引起的发病。曾提出过在具有遗传倾向的人群中,发生由炎症性肠病等而引起的肝门静脉菌血症,随后TNF-α分泌由被激活的库普弗(Kupffer)细胞而增加,发生肝内病变的机制,但尚未明确准确的病因(Clinical andMolecular Hepatology,韩国肝病学杂志,第10卷3s号,第36页至第53页,2004)。
最近,公开了包含干细胞的组合物(韩国授权专利第10-2159630号)乃至包含多种细菌的制剂(美国专利公开第2021-0008128号)预防或治疗胆汁淤积性肝病的的效果,但尚未公开包含源自乳酸菌的柠檬明串珠菌菌株或其培养物作为有效成分的预防或治疗胆汁淤积性肝病的效果。
在这种背景下,本发明人进行了研究以寻找利用几乎没有毒性及副作用的乳酸菌来预防和治疗胆汁淤积性肝病的物质,研究结果,确认到柠檬明串珠菌菌株或其培养物具有预防或治疗原发性胆汁性肝硬化或原发性硬化性胆管炎的效能,从而,完成了本发明。
发明内容
本发明的目的在于,提供一种用于预防或治疗胆汁淤积性肝病的药物组合物,其包含柠檬明串珠菌菌株作为有效成分。
另外,本发明的其他目的在于,提供一种用于预防或改善胆汁淤积性肝病的食品组合物或食品添加剂组合物,其包含柠檬明串珠菌菌株作为有效成分。
另外,本发明的其他另一目的在于,提供一种用于预防或改善家畜的胆汁淤积性肝病的饲料组合物或饲料添加剂组合物,其包含柠檬明串珠菌菌株作为有效成分。
为了达成所述目的,本发明提供一种用于预防或治疗胆汁淤积性肝病的药物组合物,其包含柠檬明串珠菌菌株或其培养物作为有效成分。
另外,本发明提供一种用于预防或改善胆汁淤积性肝病的食品组合物或食品添加剂组合物,其包含柠檬明串珠菌菌株或其培养物作为有效成分。
另外,本发明提供一种用于预防或改善家畜的胆汁淤积性肝病的饲料组合物或饲料添加剂组合物,其包含柠檬明串珠菌菌株或其培养物作为有效成分。
发明效果
根据本发明的柠檬明串珠菌菌株或其培养物对各种胆汁淤积性肝病表现出优异的预防和治疗效果,因此,可有效用作用于治疗、预防或改善人或动物的胆汁淤积性肝病的组合物。
附图说明
图1是示出将柠檬明串珠菌WiKim0104菌株处理到诱导胆道结扎(Bileductligation)的动物模型后,观察处死小鼠的肝组织的照片的图。
图2是示出将柠檬明串珠菌WiKim0104菌株处理到诱导胆道结扎(Bileductligation)的动物模型后,对处死小鼠的肝组织进行H&E染色观察肝细胞坏死的照片的图。
图3是示出将柠檬明串珠菌WiKim0104菌株处理到诱导胆道结扎(Bileductligation)的动物模型后,评价处死小鼠的肝组织的细胞坏死程度的图表的图。
图4是示出将柠檬明串珠菌WiKim0104菌株处理到诱导胆道结扎(Bileductligation)的动物模型后,用天狼星红(Sirius red)染色处死小鼠的肝组织后观察肝细胞纤维化的照片的图。
图5是示出将柠檬明串珠菌WiKim0104菌株处理到诱导胆道结扎(Bileductligation)的动物模型后,评价处死小鼠的肝组织的天狼星红%阳性面积(sirus red%positive area)及纤维化指数程度的图表的图。
图6是示出将柠檬明串珠菌WiKim0104菌株处理到诱导胆道结扎(Bileductligation)的动物模型后,利用从处死小鼠的肝组织分离的RNA合成的cDNA测量α-SMA及Col1a1表达量的图表的图。
图7是示出将柠檬明串珠菌WiKim0104菌株处理到诱导胆道结扎(Bileductligation)的动物模型后,利用从处死小鼠的肝组织分离的RNA合成的cDNA测量IL-6及IL-1β表达量的图表的图。
具体实施方式
本发明的包含柠檬明串珠菌菌株或其培养物作为有效成分的组合物具有预防或治疗胆汁淤积性肝病的效果,并且可以用作药物组合物。
本发明的柠檬明串珠菌菌株是乳酸菌菌株。所述柠檬明串珠菌菌株是一种益生菌,具有乳酸菌的一般的缓解肠道紊乱效果及免疫增强效果。众所周知,明串珠菌属的乳酸菌具有缓解肠道紊乱效果及免疫增强效果。
所述柠檬明串珠菌菌株,可以为柠檬明串珠菌WiKim0104菌株,并具有SEQ ID NO:1的核酸序列,但不限于此。
所述柠檬明串珠菌菌株可以在MRS液体培养基接种0.1%至10%,并在25℃至37℃的温度下培养4小时至48小时来使用。
所述培养方法优选为静态培养法,但不限于此。
在本发明中,“益生菌(probiotics)”是存活于包括人在内的动物的胃肠器官内,改善宿主的肠内微生物环境,从而对宿主的健康有利的微生物。益生菌是一种具有益生菌活性的活的微生物,其具有单一或复合菌株形态,当以干燥的细胞形态或发酵产物形态用于人或动物的情况下,能够对宿主的肠道菌群产生有利的影响。
所述胆汁淤积性肝病可以为肺性胆汁淤积性肝病、肾性胆汁淤积性肝病或肝性胆汁淤积性肝病,但不限于此。
包含在根据本发明的组合物中的柠檬明串珠菌菌株可以以活菌体或死菌体存在,还可以以干燥或冻干形式存在。另外,柠檬明串珠菌菌株的培养物可以为有效成分,并且在所述培养物可以包括活菌培养液或死菌上清液。适合包含在各种组合物中的乳酸菌的形态和配制方法是本领域技术人员众所周知的。
所述组合物可以通过口服或胃肠外给药。胃肠外给药可以通过静脉注射、皮下注射、肌肉注射、腹腔注射、经皮给药、局部给药、鼻内给药、肺内给药及直肠内给药等方式给药,优选地,可以通过静脉注射的方法给药,但不限定于此。
所述组合物的适当给药量可以根据配制方法、给药方式、患者的年龄、体重、性别、疾病状态、饮食、给药时间、给药途径、排泄速度及反应敏感性之类的因素给出多种处方。
在将本发明的组合物用作药物组合物的情况下,除上述有效成分外,本发明的药剂学组合物可以使用药剂学上有效、生理学上可接受的辅助剂来制备,所述辅助剂可以使用赋形剂、崩解剂、甜味剂、结合剂、包衣剂、膨胀剂、润滑剂、滑泽剂或香味剂等。
为了给药,除上述有效成分以外,所述药物组合物还可以通过包含一种以上的药学上可接受的载体来优选地配制为药物组合物。
例如,为了配制为片剂或胶囊剂,有效成分可以与乙醇、甘油、水等之类的口服、无毒性的药学上可接受的非活性载体结合。并且,可以根据需要包含适当的结合剂、润滑剂、崩解剂及发色剂或混合物。适当的结合剂包括淀粉、明胶、葡萄糖或β-乳糖之类的天然糖、玉米甜味剂、阿拉伯胶、黄芪胶或油酸钠之类的天然或合成胶、硬脂酸钠、硬脂酸镁、苯甲酸钠、醋酸钠、氯化钠等,但不限定于此。崩解剂包括淀粉、甲基纤维素、琼脂、膨润土、黄原胶等,但不限定于此。在以液体溶液的形态配制的组合物中可接受的药剂学载体可以使用适于灭菌及活体的生理盐水、灭菌水、林格氏液、缓冲生理盐水、白蛋白注射溶液、葡萄糖溶液、麦芽糊精溶液、甘油、乙醇及混合一种以上这些成分来使用,可以根据需要添加抗氧化剂、缓冲液、抑菌剂等其他常规的添加剂。并且,还可以添加稀释剂、分散剂、表面活性剂、结合剂及润滑剂来配制为水溶液、悬浮液、乳浊液等之类的注射用剂型、丸药、胶囊、颗粒或片剂。
进而,可以将Remington’s Pharmaceutical Science,Mack PublishingCompany,Easton PA中公开的方法用作本发明相关技术领域的适当的方法,根据各疾病或成分来优选地配制。
本发明的包含柠檬明串珠菌菌株或其培养物作为有效成分的组合物,可以用作用于预防或改善胆汁淤积性肝病的食品组合物或食品添加剂组合物。
所述食品组合物可以以保健功能食品的形式存在。
所述“保健功能食品”是指根据有关保健功能食品的法律,使用具有对人体有用的功能性的原料或成分制备及加工的食品(第三条第一项),“功能性”是指通过调节营养素或生理学作用等之类的保健用途来在人体的结构及功能中获得有用的效果(同一条的第二项)。
所述食品组合物还可以包括食品添加物,若无特别规定,“食品添加物”是否适当则根据韩国食品药品监督管理局认可的韩国食品添加物法典的总则及通常的试验方法等并按照与相关品种有关的规格及标准来判定。
收录于上述“食品添加物法典”中的品种有:例如酮类、甘氨酸、柠檬酸钾、烟酸、肉桂酸等化学合成品、柿子色素、甘草提取物、结晶纤维素、瓜尔豆胶等天然添加物、L-谷氨酸钠制剂、面类添加碱剂、防腐剂、焦油色素制剂等混合制剂类。
包含本发明的有效成分的食品可以为面包、糕类、干果类、糖果类、巧克力类、口香糖、果酱类之类的饼干类、冰淇淋类、冰果类、冰淇淋粉末类之类的冰淇淋制品类、牛奶类、低脂牛奶类、乳糖分解牛奶、加工乳类、山羊奶、发酵乳类、黄油乳类、浓缩乳类、奶油类、黄油类、天然奶酪、加工奶酪、奶粉类、乳清类之类的乳加工品类、肉食加工品、蛋加工品、汉堡包之类的肉食制品类、鱼饼、火腿、香肠、培根等鱼肉制品之类的鱼肉制品类、拉面类、干面类、生面类、汤面类、豪华干面类、改良熟面类、冷冻面类、意大利面类之类的面类、水果饮料、蔬菜类饮料、碳酸饮料、豆乳类、酸奶等的乳酸菌饮料、混合饮料之类的饮料、酱油、黄豆酱、辣椒酱、干黄酱、清国酱、混合酱、食醋、酱类、番茄酱、咖喱、调味汁之类的调味食品、人造黄油、起酥油以及比萨,但不限定于此。
除上述以外,本发明的组合物还可以包含多种营养剂、维生素、电解质、风味剂、着色剂、果胶酸及其盐、海藻酸及其盐、有机酸、保护性胶体增稠剂、pH调节剂、稳定剂、防腐剂、甘油、乙醇、用于碳酸饮料的碳酸化剂等。此外,本发明的组合物还可以包含用来制备天然果汁、果汁饮料及蔬菜饮料的果肉。这些成分可单独或组合来使用。
包含本发明的有效成分的饮料组合物对其他成分没有特别限制,可以与普通饮料一样包含多种香味剂或天然碳水化合物等。上述天然碳水化合物的例有单糖(例如葡萄糖、果糖等)、二糖(例如麦芽糖、蔗糖等)、多糖(例如糊精、环糊精等)之类的普通的糖、以及木糖醇、山梨糖醇、赤藓糖醇等糖醇。除上述以外,还可以有利地将天然香味剂(索马甜、甜叶菊提取物(例如莱鲍迪甙A、甘草酸等))以及合成香味剂(糖精、阿巴斯甜等)用作香味剂。
并且,本发明的包含柠檬明串珠菌菌株或其培养物作为有效成分的组合物,可以用作用于预防或改善家畜的胆汁淤积性肝病的饲料组合物或饲料添加剂组合物。
在将所述组合物制备为饲料添加剂的情况下,所述组合物可以制备为20%至90%的高浓缩液或粉末或颗粒形态。所述饲料添加剂还可以包含柠檬酸、富马酸、己二酸、乳酸、苹果酸等有机酸或磷酸钠、磷酸钾、酸性焦磷酸盐、聚磷酸盐(聚合磷酸盐)等磷酸盐或多酚、儿茶素、α生育酚、迷迭香提取物、维生素C、绿茶提取物、甘草提取物、甲壳素、鞣酸、植酸等天然抗氧化剂中的一种或一种以上。在制备为饲料的情况下,所述组合物可以配制为普通的饲料形态,可以包含普通的饲料成分。
所述饲料及饲料添加剂还可以包含谷物,例如由粉碎或破碎的小麦、燕麦、大麦、玉米及大米;植物蛋白饲料,例如以芸苔、大豆以及葵花为主要成分的饲料;动物蛋白饲料,例如血粉、肉粉、骨粉及鱼粉;以及糖分及乳制品,例如各种奶粉及乳浆粉末组成的干燥成分等,此外还可以包含营养补充剂、消化及吸收促进剂、生长促进剂等。
所述饲料添加剂可以单独向动物给药,或者在食用载体中与其他饲料添加剂组合来给药。并且,所述饲料添加剂可以在追肥饲料中,或是将其与动物饲料直接混合,或者在饲料外以单独剂型的方式轻松地向动物给药。在将所述饲料添加剂与动物饲料单独给药的情况下,可以与相关领域公知的药学上可接受的食用载体组合制备为即时释放或缓释剂型。所述食用载体可以为固体或液体载体,例如玉米淀粉、乳糖、蔗糖、玉米片、花生油、橄榄油、芝麻油及丙二醇。在使用固体载体的情况下,饲料添加剂可以为片剂、胶囊剂、散剂、含片或糖衣片剂或微分散性形态的追肥饲料。在使用液体载体的情况下,饲料添加剂可以为明胶软质胶囊剂,或者糖浆剂或悬浮液、乳液剂或溶液剂的剂型。
并且,所述饲料及饲料添加剂可以包含辅助剂,例如,保存剂、稳定剂、湿润剂或润滑剂、溶液促进剂等。所述饲料添加剂通过浸注、喷雾或混合的方式添加于动物的饲料来使用。
本发明的饲料或饲料添加剂可以适用于包括哺乳类、家禽及鱼类的大多数动物的饮食中。
作为所述哺乳类,不仅可以用于猪、牛、马、羊、兔子、啮齿类动物以及用于实验的啮齿动物即小鼠、仓鼠、豚鼠,还可以用于宠物(例如狗、猫)等,作为所述家禽类,可以用于鸡、火鸡、鸭、鹅、雉鸡以及鹌鹑等,作为所述鱼类,可以用于为鲤鱼及鳟鱼等,但不限定于此。
实施方式
下面,通过实施例对本发明进行更详细地说明。这些实施例仅用于更详细地说明本发明,并且,对于本领域的普通技术人员来说根据本发明的主旨本发明的范围不受这些实施例的限制是显而易见的。
实施例1.培养菌株
柠檬明串珠菌WiKim0104(保藏号KCCM12420P)菌株经保藏者韩国食品研究所许可分配得到,并进行了实验。
将所述分配得到的柠檬明串珠菌WiKim0104菌株以1%接种于30ml的MRS液体培养基中,在30℃的温度下静置培养18小时。培养后,以3000rpm的转速离心分离10分钟,然后单独保存培养液,并用磷酸盐缓冲溶液(PBS,phosphate buffered saline)洗涤菌体3次,以除去剩下的培养基成分。
实施例2.确认动物模型中胆汁淤积抑制效果
2-1.实验动物小鼠条件
实验所用实验动物为8周龄雄性C57BL6小鼠,在保持室温20±2℃、湿度55±15%的SPF环境的动物饲养室中,经过1周的稳定期后在实验期间饲养。饲料供给不含抗生素的普通颗粒饲料,随时饮水,适应饲料1周后进行实验。
2-2.制备诱导胆道结扎(Bile duct0ligation)的动物模型
细胞毒性胆汁在肝细胞中的积累是胆汁淤积性肝病的重要原因,例如原发性胆汁性肝硬化(PBC)及原发性硬化性胆管炎(PSC)。为了确认柠檬明串珠菌菌株对胆汁淤积性疾病的功效,进行胆管结扎(Bileduct ligation)。
将上述实施例2-1中准备的小鼠将胆管用不可吸收的手术线结扎2次。作为对照组,在不结扎胆管的情况下,用相同的方法进行手术。手术后,根据开始给药当天的体重、黄疸、尿液颜色变化等为准,按照Z排列法对小鼠进行分组。分组后,对实验组口服给药柠檬明串珠菌WiKim0104菌株组合物,以2×109CFU/天,每天一次,0.2mL/head体积,持续2周。对照组吃等量的PBS。对于所有动物,每天观察一次一般症状,每天2次检查是否存在濒临死亡和死亡的动物,观察从手术后到给药结束时为止。停止给药2周后,处死小鼠。
2-3.肝组织病理分析
对上述2-2中准备的处死小鼠进行尸检,然后进行组织分析。对腹部器官进行目视检查,确认内脏器官有无异常,并提取肝组织和肠组织。将提取的肝组织用生理盐水洗涤并用滤纸除去水分后,拍摄肝形状并进行比较,将结果示于图1。
如图1所示,确认到诱导胆管结扎(Bileduct ligation)的对照组与手术对照组相比,肝的颜色变黄,并且,给药柠檬明串珠菌时,变化为与正常小鼠的手术对照组相似的肝形状及颜色。
此外,为了进行组织病理学检查,将肝组织固定在10%中性福尔马林中,对固定的组织进行修剪、脱水及石蜡包埋等的一般的组织处理过程制作成石蜡块之后进行切片。对切好的组织切片进行苏木精和伊红(Hematoxylin&Eosin,H&E)染色,对肝细胞坏死(ecrosis)、胆管细胞增殖、门脉水肿进行组织学分析,将结果示于图2及图3。
如图2及图3所示,经H&E染色结果,在BDL模型对照组中观察到肝细胞坏死部分(箭头),并且,在胆管周围观察到胆管细胞的增殖。在柠檬明串珠菌菌株处理组中,可以确认到肝细胞坏死显著减少,并且,根据组织病理学评分,肝细胞坏死评分显示显著减少。
2-4.评价由胆汁淤积引起的肝纤维化
使用从上述2-2中准备的处死小鼠的肝细胞进行肝纤维化分析。众所周知肝纤维化与肝细胞坏死一起被认为是胆汁淤积性肝病的主要病理症状之一,为了评价由胆汁淤积而引起的肝纤维化,在图4及图5中示出用天狼星红(sirus red)进行染色后确认的结果以及通过组织病理评价显示纤维化指数的图表。
如图4所示,确认到在用柠檬明串珠菌菌株处理的组中,由BDL增加的天狼星红%阳性面积(sirus red%positive area)显著减少,并且,如图5所示,与对照组相比,用柠檬明串珠菌菌株处理的组中,由BDL增加的纤维化评分显著降低。
2-5.分析与肝纤维化及炎症相关的细胞因子表达量
从上述2-2中准备的稀释小鼠的肝组织中分离RNA,通过q-RT-PCR方法确认与纤维化和炎症相关的基因标记α-SMA(alpha-smooth muscle actin)和Col1a1(collagen type1a)的变化。各组小鼠肝组织中添加1ml的Trizol,用匀浆器(homogenizer)粉碎组织后,用氯仿(Chloroform)和异丙醇(isopropanol)分离RNA,然后,合成cDNA。使用合成的cDNA观察纤维化和炎性细胞因子的变化,将其结果示于图6及图7中。
如图6所示,确认到与BDL对照组相比,在用柠檬明串珠菌菌株处理的组中α-SMA和Col1a1的表达显著减少。
如图7所示,确认到与BDL对照组相比,在用柠檬明串珠菌菌株处理的组中IL-6及IL-1β的表达显著减少。
鉴于上述结果,可以确认到处理根据本发明的组合物的情况下,对由胆汁淤积而引起的肝细胞损伤、纤维化及炎症表现出优异的效果,从而,可用作用于预防及治疗胆汁淤积性肝病的组合物。
[保藏编号]
保藏机构名称:韩国微生物保藏中心(国外)
保藏编号:KCCM12420P
保藏日期:20181214
国际承认用于专利程序的微生物保藏布达佩斯条约
国际格式
To.韩国食品研究院 本页底部指明的国际保藏机构
大韩民国全罗北道完州郡伊西面 据规则7.1出具的原件的收据
农生命路245,55356
在适用规则6.4(d)的情况下,该日期是获得国际保藏机构资格的日期。
序列表
<110> 利斯科生物科技(Liscure Biosciences)
<120> 柠檬明串珠菌WiKim0104(Leuconostoc citreum WiKim0104)
<130> WiKim0104
<150> KR 10-2021-0017842
<151> 2021-02-08
<160> 1
<170> KoPatentIn 3.0
<210> 1
<211> 1430
<212> DNA
<213> 柠檬明串珠菌(Leuconostoc citreum)
<400> 1
gatgaacgct ggcggcgtgc ctaatacatg caagtcgaac gcgcagcgag aggtgcttgc 60
acctttcaag cgagtggcga acgggtgagt aacacgtgga taacctgcct caaggctggg 120
gataacattt ggaaacagat gctaataccg aataaaactt agtatcgcat gatatcaagt 180
taaaaggcgc tacggcgtca cctagagatg gatccgcggt gcattagtta gttggtgggg 240
taaaggctta ccaagacgat gatgcatagc cgagttgaga gactgatcgg ccacattggg 300
actgagacac ggcccaaact cctacgggag gctgcagtag ggaatcttcc acaatgggcg 360
caagcctgat ggagcaacgc cgcgtgtgtg atgaaggctt tcgggtcgta aagcactgtt 420
gtatgggaag aaatgctaaa atagggaatg attttagttt gacggtacca taccagaaag 480
ggacggctaa atacgtgcca gcagccgcgg taatacgtat gtcccgagcg ttatccggat 540
ttattgggcg taaagcgagc gcagacggtt gattaagtct gatgtgaaag cccggagctc 600
aactccggaa tggcattgga aactggttaa cttgagtgtt gtagaggtaa gtggaactcc 660
atgtgtagcg gtggaatgcg tagatatatg gaagaacacc agtggcgaag gcggcttact 720
ggacaacaac tgacgttgag gctcgaaagt gtgggtagca aacaggatta gataccctgg 780
tagtccacac cgtaaacgat gaatactagg tgttaggagg tttccgcctc ttagtgccga 840
agctaacgca ttaagtattc cgcctgggga gtacgaccgc aaggttgaaa ctcaaaggaa 900
ttgacgggga cccgcacaag cggtggagca tgtggtttaa ttcgaagcaa cgcgaagaac 960
cttaccaggt cttgacatcc tttgaagctt ttagagatag aagtgttctc ttcggagaca 1020
aagtgacagg tggtgcatgg tcgtcgtcag ctcgtgtcgt gagatgttgg gttaagtccc 1080
gcaacgagcg caacccttat tgttagttgc cagcattcag ttgggcactc tagcgagact 1140
gccggtgaca aaccggagga aggcggggac gacgtcagat catcatgccc cttatgacct 1200
gggctacaca cgtgctacaa tggcgtatac aacgagttgc caacctgcga aggtgagcta 1260
atctcttaaa gtacgtctca gttcggactg cagtctgcaa ctcgactgca cgaagtcgga 1320
atcgctagta atcgcggatc agcacgccgc ggtgaatacg ttcccgggtc ttgtacacac 1380
cgcccgtcac accatgggag tttgtaatgc ccaaagccgg tggcctaacc 1430
Claims (12)
1.一种用于预防或治疗胆汁淤积性肝病的药物组合物,其中,包含柠檬明串珠菌菌株或其培养物作为有效成分。
2.根据权利要求1所述的用于预防或治疗胆汁淤积性肝病的药物组合物,其中,所述柠檬明串珠菌菌株是具有SEQ ID NO:1的核酸序列的柠檬明串珠菌WiKim0104(保藏编号KCCM12420P)菌株。
3.根据权利要求1所述的用于预防或治疗胆汁淤积性肝病的药物组合物,其中,所述胆汁淤积性肝病为原发性胆汁性肝硬化、原发性硬化性胆管炎。
4.根据权利要求1所述的用于预防或治疗胆汁淤积性肝病的药物组合物,其中,所述组合物通过口服给药或胃肠外给药方式给药。
5.根据权利要求4所述的用于预防或治疗胆汁淤积性肝病的药物组合物,其中,所述胃肠外给药通过静脉注射、皮下注射、肌肉注射、腹腔注射、经皮给药、局部给药、鼻内给药、肺内给药或直肠内给药。
6.一种用于预防或改善胆汁淤积性肝病的食品组合物,其中,包含柠檬明串珠菌菌株或其培养物作为有效成分。
7.根据权利要求6所述的用于预防或改善胆汁淤积性肝病的食品组合物,其中,所述食品为保健功能食品。
8.根据权利要求6所述的用于预防或改善胆汁淤积性肝病的食品组合物,其中,所述食品为选自由面包、年糕、糖果、巧克力、口香糖、冰淇淋、牛奶、奶酪、加工肉制品、加工鱼制品、泡菜、酱油、大酱、辣椒酱、春酱、清国酱、醋、番茄酱、咖喱、调味汁、饮料及发酵油组成的组中的一种食品。
9.一种用于预防或改善胆汁淤积性肝病的食品添加剂组合物,其中,包含柠檬明串珠菌菌株或其培养物作为有效成分。
10.一种用于预防或改善家畜的胆汁淤积性肝病的饲料组合物,其中,包含柠檬明串珠菌菌株或其培养物作为有效成分。
11.根据权利要求10所述的用于预防或改善家畜的胆汁淤积性肝病的饲料组合物,其中,所述家畜为选自由猪、牛、马、绵羊、兔、山羊、小鼠、仓鼠、豚鼠、狗、猫、鸡、火鸡、鸭、鹅、雉鸡、鹌鹑、鲤鱼、鲫鱼及鳟鱼而组成的组中的一种。
12.一种用于预防或改善家畜的胆汁淤积性肝病的饲料添加剂组合物,其中,包含柠檬明串珠菌菌株或其培养物作为有效成分。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0017842 | 2021-02-08 | ||
KR10-2022-0014833 | 2022-02-04 | ||
KR1020220014833A KR20220114491A (ko) | 2021-02-08 | 2022-02-04 | 류코노스톡 시트래움 균주를 유효성분으로 포함하는 담즙정체성 간질환의 예방 또는 치료용 약학 조성물 |
PCT/KR2022/001871 WO2022169338A1 (ko) | 2021-02-08 | 2022-02-07 | 류코노스톡 시트래움 균주를 유효성분으로 포함하는 담즙정체성 간질환의 예방 또는 치료용 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117320736A true CN117320736A (zh) | 2023-12-29 |
Family
ID=89255783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280014031.5A Pending CN117320736A (zh) | 2021-02-08 | 2022-02-07 | 包含柠檬明串珠菌菌株作为有效成分的用于预防或治疗胆汁淤积性肝病的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117320736A (zh) |
-
2022
- 2022-02-07 CN CN202280014031.5A patent/CN117320736A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019396103B2 (en) | Pharmaceutical composition for preventing or treating cancer, comprising Weissella cibaria WIKIM28 as active ingredient | |
JP2019182763A (ja) | 組成物、およびそれを含む食品および飼料 | |
US20220062355A1 (en) | Pharmaceutical composition comprising lactobacillus sakei wikim30 as active ingredient for prevention or treatment of cancer | |
CN117320736A (zh) | 包含柠檬明串珠菌菌株作为有效成分的用于预防或治疗胆汁淤积性肝病的药物组合物 | |
EP4289441A1 (en) | Pharmaceutical composition comprising leuconostoc citreum strain as active ingredient for preventing or treating cholestatic liver injuries | |
CN117337187A (zh) | 包含柠檬明串珠菌菌株作为有效成分的用于预防或治疗肠道损伤的药物组合物 | |
US20240091281A1 (en) | Pharmaceutical composition for preventing or treating intestinal damage comprising leuconostoc citreum strain as active ingredient | |
KR20220114491A (ko) | 류코노스톡 시트래움 균주를 유효성분으로 포함하는 담즙정체성 간질환의 예방 또는 치료용 약학 조성물 | |
RU2792300C2 (ru) | Фармацевтическая композиция для предотвращения или лечения рака, содержащая weissella cibaria wikim28 в качестве активного ингредиента | |
JP7456668B2 (ja) | ワイセラ・シバリアwikim28を有効成分として含む癌の予防又は治療用薬学組成物 | |
KR102339314B1 (ko) | 와이셀라 시바리아 wikim28을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 | |
US20240115628A1 (en) | Pharmaceutical composition for preventing or treating fibrosis comprising leuconostoc citreum strain as active ingredient | |
JP7177271B2 (ja) | 抗癌活性を有するラクトバチルス・ファーメンタムWiKim0102及びこれを有効成分として含む組成物 | |
EP4134089A1 (en) | Pharmaceutical composition comprising genus leuconostoc strain as active ingredient for prevention or treatment of cancer | |
CN117320737A (zh) | 包含柠檬明串珠菌菌株作为有效成分的用于预防或治疗纤维化的药物组合物 | |
KR20220114490A (ko) | 류코노스톡 시트래움 균주를 유효성분으로 포함하는 장 손상의 예방 또는 치료용 약학 조성물 | |
KR20220114489A (ko) | 류코노스톡 시트래움 균주를 유효성분으로 포함하는 섬유화증의 예방 또는 치료용 약학 조성물 | |
KR20220094153A (ko) | 와이셀라 시바리아 균주 유래 나노소포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 | |
KR20220094155A (ko) | 락토바실러스 사케아이 균주 유래 나노소포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 | |
KR20220094154A (ko) | 락토바실러스 퍼멘텀 균주 유래 나노소포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 | |
CN115551523A (zh) | 包含明串珠菌属菌株作为有效成分的癌症的预防或治疗用药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |